Cargando…

No two classes of biosimilars: Urgent advice to the US Congress and the FDA

WHAT IS KNOWN AND OBJECTIVE: The United States is the only country with legislation to approve two classes of biosimilars. One has “no clinically meaningful difference” from the reference product, and when it is tested for switching and alternating, it can receive an interchangeable status. The obje...

Descripción completa

Detalles Bibliográficos
Autor principal: Niazi, Sarfaraz K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796791/
https://www.ncbi.nlm.nih.gov/pubmed/35869625
http://dx.doi.org/10.1111/jcpt.13743